A carregar...
Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: A dual-center, propensity score matched analysis
Ruxolitinib is a JAK1/2 inhibitor approved for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Recent data has suggested the possibility of increased infectious and secondary malignancy rates in patients treated with ruxolitinib. We conducted a dual-center, retrospective study of 202...
Na minha lista:
| Publicado no: | Leuk Lymphoma |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7771191/ https://ncbi.nlm.nih.gov/pubmed/31711337 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2019.1688323 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|